Welcome to our dedicated page for Theravance Biopharma news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Biopharma stock.
Theravance Biopharma, Inc. (NASDAQ: TBPH) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. The company's mission is to pioneer a new generation of small-molecule drugs that better meet patient needs by maximizing efficacy while limiting systemic side effects.
Theravance Biopharma has a strong focus on inflammation and immunology and aims to deliver Medicines that Make a Difference® in people's lives. The company's research expertise has led to the development of the FDA-approved YUPELRI® (revefenacin) inhalation solution, the first once-daily, nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Theravance Biopharma co-promotes YUPELRI with Viatris Inc. under a profit and loss sharing arrangement.
Another promising product in Theravance Biopharma's pipeline is ampreloxetine, a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). This drug has the potential to be a first-in-class therapy, addressing a significant unmet medical need for MSA patients.
The company is also involved in strategic collaborations with other pharmaceutical companies to expand its reach and enhance its product pipeline. Their current projects and partnerships are aimed at furthering the development and commercialization of innovative therapies.
Financially, Theravance Biopharma has shown consistent performance, with significant growth in YUPELRI net sales and robust clinical trial activity. Recent achievements include positive results from a Phase III clinical trial of YUPELRI in China and ongoing enrollment in the Phase 3 CYPRESS study for ampreloxetine. These milestones underscore the company's commitment to delivering impactful therapies and driving shareholder value.
Theravance Biopharma continues to leverage its organ-selective drug development expertise to create value and improve patient outcomes. For more information, please visit www.theravance.com.
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference and host in-person meetings with investors. The event will include a Fireside Chat on May 20 at 11:30 AM EDT. A webcast will be available on Theravance.com for 30 days.
Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Participants can pre-register for the call by telephone or listen to the conference call live via the internet on Theravance Biopharma's website. A replay of the webcast will be available on the company's website for 30 days through June 12, 2024.
FAQ
What is the current stock price of Theravance Biopharma (TBPH)?
What is the market cap of Theravance Biopharma (TBPH)?
What is Theravance Biopharma's primary focus?
What is YUPELRI?
What is ampreloxetine?
Who are Theravance Biopharma’s strategic partners?
What recent achievements has Theravance Biopharma made?
Where can I find more information about Theravance Biopharma’s products?
What is the purpose of the CYPRESS study?
How does Theravance Biopharma create shareholder value?
What is Theravance Biopharma’s mission?
How can I listen to Theravance Biopharma's conference calls?
